First Patient Dosed in Phase Ib/II Trial Evaluating Tiprelestat
tiakis Biotech AG announced today that a first patient has been dosed in the COMCOVID trial, a Phase Ib/II trial evaluating the Company’s key investigational product Tiprelestat. The COMCOVID trial is a nationwide study in Germany to evaluate safety and efficacy of Tiprelestat in hospitalized COVID-19 patients. The trial welcomes participation from additional study centers.
Tiprelestat is an anti-inflammatory human protein to be administered by intravenous infusion. It is anticipated that Tiprelestat, upon administration, will alleviate both pulmonary and systemic inflammation commonly associated with severe cases of COVID-19.
The randomized, double-blind, placebo-controlled Phase Ib/II trial is expected to enroll 296 patients receiving either Tiprelestat or placebo. Tiprelestat will be administered to patients hospitalized due to COVID-19 with the goal of reducing the duration of severe COVID-19.
“We are pleased to announce that the first participant has been dosed in our latest clinical trial as we look to bring a potential new treatment option to severely affected COVID-19 patients,” says Diethelm Siebuhr, tiakis Biotech AG co-CEO.
The COMCOVID trial is co-funded by the Germany Ministry of Education and Research (“BMBF”) and tiakis is proud to support the ongoing efforts to develop treatment options for COVID-19 thereby lessening the future impact of the disease.
More News
tiakis Biotech AG and Northway Biotech collaborate
tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful ...
Read more …
Natural substances show promise against coronavirus
Three natural compounds present in foods like green tea, olive oil and red wine are promising candidates for the development of drugs against the coronavirus. ...
Read more …
Evotec: € 7.5 m grant for development of COVID-19 therapeutic
Evotec SE announced that the Company has been selected by the German Federal Ministry of Education and Research (“BMBF”) to receive a grant for the ...
Read more …